A new multicenter clinical study highlights a potential new approach for patients with advanced kidney cancer, providing a clearer picture of how the disease works beneath the surface and providing measurable clinical responses.
Results from the ARC-20 Phase 1 clinical trial show that Kasdatifan, an oral investigational therapy designed to inhibit hypoxia-inducible factor 2α, produced durable tumor responses with a manageable safety profile in patients with heavily pretreated clear cell renal cell carcinoma, the most common form of kidney cancer. This study nature.
For a disease that often adapts and resists treatment, the results provide an early signal that a more targeted approach may help slow the curve.
“These findings are encouraging and suggest that we may be able to better understand which patients benefit from targeting this pathway,” said study co-author Jamie Marchan, MD, co-leader of the Translational Clinical Oncology Research Program and director of the Phase 1 Clinical Trials Program at the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Clear cell renal cell carcinoma is primarily caused by aberrant activation of HIF-2α, a transcription factor that helps tumors grow, spread, and survive in hypoxic environments.
In many ways, this pathway acts like a control center inside a tumor, turning on signals that promote tumor growth. Although initial treatments have attempted to interrupt this process, response rates remain limited in patients whose disease progresses after initial treatment.
Kasdatifan is designed to block that signal more effectively, with properties aimed at improving how the drug reaches and engages tumor tissue.
The ARC-20 study enrolled 127 patients with treatment-resistant, progressive disease, most of whom had received multiple prior treatments. The observed objective response rate among patients receiving the recommended dose was 35%. The overall response rate in the study population was 31%, with more than 80% of patients achieving disease control, including stable disease.
Responses occurred within a median of approximately 3 months. In some cases, tumors did not plateau early and continued to shrink over time.
These results are significant in highly pretreated populations. They suggest that this approach may provide meaningful activity for patients with limited options. ”
Jamie Marchan, MD, Co-Leader, Translational and Clinical Oncology Research Program, Sylvester Comprehensive Cancer Center
The study was a single-arm, early-stage trial and was not designed to directly compare Kasdatifan with other treatments. Differences in study design and patient populations also limit comparisons between trials.
A feature of this research is how closely what happens in the clinical setting and what happens inside the tumor are closely linked. The researchers observed that reductions in serum erythropoietin, a marker regulated by HIF-2α, were associated with higher response rates, lower rates of disease progression, and longer progression-free survival.
Tumor analysis reinforced that pattern. Patients whose tumors showed higher levels of HIF-2α-related activity were likely to benefit, suggesting that the drug is involved in the pathway it was designed to target. Taken together, these findings begin to map a clearer relationship between tumor biology and treatment response, helping researchers understand not just whether treatments work, but why.
“This is an important step in understanding how tumor biology can help guide treatment decisions,” Marchand said.
Kasdatifan’s safety profile was consistent with other treatments targeting the same pathway. Common side effects included anemia, fatigue, and hypoxia, most of which were managed with supportive care and dose adjustments. Study drug-related treatment discontinuations were rare, and no treatment-related deaths were reported.
Although the results are encouraging, the researchers emphasize that additional studies are needed to better define Kasdatifan’s role in the treatment of advanced kidney cancer. Ongoing clinical trials are evaluating the treatment in combination with other treatments to determine whether outcomes can be further improved.
Kasdatifan is still under investigation in this setting and is not yet part of standard treatment.
For now, the ARC-20 study offers a clearer glimpse into how targeting a central pathway in cancer may impact outcomes, especially in tumors that appear to rely on its signals.
“In a disease that can change and adapt over time, just being able to see its underlying biology more clearly represents a meaningful advance and helps guide where research and treatment strategies go next,” said Dr. Marchan.
sauce:
University of Miami Miller School of Medicine
Reference magazines:
TK Choeiri Others. (2026). Kasdatifan exhibits sustained responses associated with HIF-2α biology in kidney cancer. Nature. DOI: 10.1038/s41586-026-10718-x. https://www.nature.com/articles/s41586-026-10718-x
